Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

LTZ Raises $20 Million in A Round for Myeloid Engager Candidates

publication date: Jul 30, 2024

LTZ Therapeutics, a Shenzhen-Redwood City, CA immunotherapy biotech, completed a Series A financing of over $20 million. The company is developing Myeloid Engager candidates to enhance the phagocytic function of monocytes and macrophages. Using reverse translational science and new insights into the tumor microenvironment, LTZ’s novel immunotherapies are expected to overcome resistance and boost anti-tumor immunity. The A round was led by new investor Lapam Capital and includes GL Ventures, also a new investor. K2 Venture Partners and Shunwei Capital participated. So far, LTZ has raised $50 million since it was founded in 2022. More details....

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here